Skip to main content
OpenTrials
Completed

NCT Number: NCT04403009

The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19

To investigate the difference of the difference between the nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the fatal Patients .The cross sectional study was undertaken to compare the clinical information (laboratory and radiologic characteristics)of nonfatal participants and fatal cases. The investigators wish figure out the clinical character of the fatal participants. The result may help the physician to find the fatal patients with COVID-19 more easily. The fatal patients with COVID-19 could be treated early.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronavirus Disease 2019 COVID-19 Character of the Severe Patients Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

20 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patients with Coronavirus Disease 2019
  • Positive result on real-time reverse-transcriptase-polymerase-chain-reaction
  • Positive result on chest computed tomography

Exclusion criteria

  • No

Treatment and study plan

No intervention

Other

no intervention

Primary outcomes

  1. Lymphocyte cell

    Time frame: 2 month

    the counting of Lymphocyte(counts/L)

  2. d-dimer

    Time frame: 2 month

    d-dimer（mg/L）

  3. PLT

    Time frame: 2 month

    the counting of Platelets（(counts/L)）

  4. CRP

    Time frame: 2 month

    the level of C-reactive protein (mg/uL)

  5. LDH

    Time frame: 2 month

    lactate dehydrogenase ( U/L)

  6. CK

    Time frame: 2 month

    creatine kinase (U/L)

  7. PT

    Time frame: 2 month

    prothrombin time(second)

  8. ALT

    Time frame: 2 month

    alanine aminotransferase(U/L)

  9. AST

    Time frame: 2 month

    aspartate aminotransferase(U/L)

  10. NK cell

    Time frame: 2 month

    natural killer cell(counts/L)

  11. PCT

    Time frame: 2 month

    procalcitonin（ng/ml）

  12. IL-6

    Time frame: 2 month

    interleukin-6(mg/L)

Secondary outcomes

  1. the clinical difference of radiologic characteristics between the fatal patients with COVID -19 and the non fatal cases

    Time frame: 2 months

    CT scan feature

Other outcomes

  1. SPO2

    Time frame: 2 month

    oxygen Saturation

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital of Guangzhou Medical University

Other

Registry information

Official study title

The Clinical Difference Between the Nonfatal Coronavirus Disease 2019 (COVID-19) Patients and the Fatal Cases With Severe COVID-19

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
May 27, 2020
Registry last updated
Mar 7, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.